Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

477 Abdominal Herniation and Gastrointestinal Symptoms in Patients With Loey Dietz Syndrome and Vascular Ehlers Danlos Syndrome
Babameto, Mary, Babovic‐Vuksanovic, Dusica , Camilleri, Michael , Wang, Xiao‐Jing

Mayo Clinic

American Journal of Gastroenterology | October 8, 2019 | Volume: 114 | Issue: 1 | Pages: S276-S277

10.14309/01.ajg.0000591440.20831.d5 Get It

INTRODUCTION: Loey Dietz syndrome (LDS) is an autosomal dominant disorder caused by a mutation in TGFBR1 - or TGFBR2. LDS is characterized by distinctive facies, tortuous arteries and aortic aneurysms predisposition to eosinophilic allergic disorders including eosinophilic esophagitis and gastritis, and other systemic findings including inflammatory bowel disease. Patients with vascular Ehlers Danlos Syndrome (vEDS) have deficiency in type III collagen and have similar vascular laxity and concomitant GI manifestations. This connective tissue vulnerability contributes to increased post-operative wound dehiscence and development of hernias. Our aim was to summarize abdominal wall and GI tract manifestations in these two rare vascular disorders at a tertiary referral center. METHODS: Data were collected via Advanced Cohort Explorer (ACE) application at Mayo Clinic. A chart review was undertaken on patients with a confirmed diagnosis of vEDS or LDS seen at Mayo Clinic in Rochester from 1994 to 2018. Diagnoses were confirmed by genetic testing and/or clinical review through the specialized medical genetics clinic. Information was extracted on vascular complications of disease, prevalence of abdominal hernias, and gastrointestinal symptoms. The study was reviewed and exempted by the Mayo Clinic IRB. RESULTS: We identified and reviewed records of 50 vEDS and 13 LDS patients; data are summarized in Tables 1 and 2. Patients were similar in age at diagnosis and gender distribution. Hernias were present in similar proportions of patients with vEDS and LDS, although ventral hernias were more frequent and the hernias were more likely to be post-operative in vEDS than in LDS. LDS patients had more aneurysms (58% vEDS vs. 76.9% LDS, P = 0.02) with higher proportion requiring arterial repair (32.7% vEDS vs. 69.2% LDS, P = 0.03). Co-morbidities more prevalent in LDS than vEDS were autonomic dysfunction, psychopathology and allergy. We did not note increase in symptoms suggestive of eosinophilic esophagitis/gastritis in the LDS patients. GI symptoms were prevalent in both disorders and largely similar, except for diarrhea and constipation which were both significantly more prevalent in LDS patients. CONCLUSION/DISCUSSION: While vEDS and LDS are both connective tissue disorders with propensity for GI symptoms, abdominal hernias and aneurysm formation, the risk of arterial rupture and co-morbidity of autonomic dysfunction, psychopathology and allergy are greater in LDS than vEDS.
352 Volumetric Laser Endomicroscopy Feature Discovery and Diagnostic Performance Optimization for Barrett’s Esophagus Dysplasia Using Laser-Targeted Biopsies With Histopathologic Correlation
McKinley, Matthew , Chang, Kenneth J. , Samarasena, Jason , Mashimo, Hiroshi , Smith, Michael S. , Béchard, Vincent , Vieth, Michael , Odze, Robert D. , Tearney, Gary J., Wang, Kenneth K. , Leggett, Cadman L. , Trindade, Arvind J. , Singh, Satish K.

Mayo Clinic

American Journal of Gastroenterology | October 8, 2019 | Volume: 114 | Issue: 1 | Pages: S207-S207

10.14309/01.ajg.0000590940.34704.29 Get It

INTRODUCTION: Volumetric laser endomicroscopy (VLE) is a high-resolution imaging modality used in Barrett’s esophagus (BE) surveillance. Established VLE scoring systems use a combination of features to guide BE dysplasia diagnosis but it remains unclear whether these features are sufficient to reach optimal VLE diagnostic performance. This study explores an exhaustive list of VLE features using one-to-one imaging to pathology correlation to develop optimal VLE diagnostic models for BE dysplasia. METHODS: In this prospective, multi-center (5 sites) study, patients with dysplastic BE underwent VLE with laser targeted regions of interest (ROIs), followed by standard surveillance endoscopy and biopsy directed to laser-marked sites. Histology was reviewed by two GI pathologists (MV, RO) who achieved a consensus diagnosis (gold-standard). ROIs were dysplastic if low-grade dysplasia (LGD), high-grade dysplasia (HGD) or intramucosal adenocarcinoma (IMC) was present. Two VLE experts (CLL, GJT) reviewed ROIs and corresponding endoscopic images to identify and define a set of VLE features associated with BE dysplasia. A multi-variable logistic regression model based on least absolute shrinkage and selection operator (LASSO) method was developed to determine the optimal diagnostic performance of these features. A decision tree model with high clinical usability also was developed to evaluate VLE diagnostic performance for real-time image interpretation. RESULTS: A total of 461 VLE ROIs with matching histology were obtained from 150 patients (Table 1). A final dataset of 55 neoplastic (LGD, 12; HGD, 24; IMC, 19) and 56 randomly selected non-dysplastic ROIs were reviewed. Twenty-eight VLE features were identified describing layering, signal intensity, surface topography, and glandular characteristics. LASSO logistic regression modeling identified 5 VLE features which when utilized optimized diagnostic performance with an area under the curve (AUC) for BE dysplasia of 0.95 (Figure 1). To improve clinical usability, a decision tree model was optimized to three levels with an AUC of 0.90 (Figure 2). CONCLUSION: This study represents the most comprehensive review of VLE features associated with BE dysplasia to date. The proposed high-performing diagnostic models suggest that VLE can be used efficiently and effectively to enhance BE surveillance by identifying ROIs for targeted biopsy. Further validation of the proposed VLE models will determine their clinical utility.
39 Impact of Cannabis Use on Chronic Pancreatitis: A 10-Year Analysis of the National Inpatient Sample Database
Mbachi, Chimezie , Barkin, Jodie A. , Wang, Yuchen , Demetria, Melchor , Barkin, Jamie S. , Kröner, Paul T. , Simons-Linares, C. Roberto

Mayo Clinic

American Journal of Gastroenterology | October 8, 2019 | Volume: 114 | Issue: 1 | Pages: S22-S22

10.14309/01.ajg.0000589688.01151.1f Get It

INTRODUCTION: Chronic pancreatitis (CP) is a debilitating chronic disease and significantly impacts patient's quality of life. There is evidence that cannabinoids reduce markers of inflammation and fibrosis in pancreatic stellate cells; Cannabis is becoming increasingly popular and there are currently 33 states in the US that have approved medical cannabis while 10 states have approved cannabis for recreational use. We investigated the national trends in prevalence, mortality, length of stay (LOS), hospitalization charges and cost of chronic pancreatitis patients and compared between cannabis-exposed (CE) and non-cannabis-exposed (non-CE). METHODS: The National Inpatient Sample (NIS) database from 2005 to 2014 was queried for all patients with a primary discharge diagnosis of CP as per the International Classification of Diseases 9 th revision (ICD-9) code 5771. Active exposure to cannabis was ascertained based on ICD-9 code 304.3X and 305.2X. We compared CE vs. non-CE patients. Outcomes included in-hospital mortality, length of stay (LOS), inflation adjusted charges and cost. Propensity match analysis for age, gender, race, median income quartile, hospital characteristics and Elixhauser comorbidity index and multivariable logistic regression models were performed using STATA 14 software. RESULTS: Over 31,481 patients with CP as the primary diagnosis were analyzed. Cannabis-exposure prevalence was 1.4% (447 patients). The mean age of CP patients was 49. Patients exposed to cannabis were younger (42 vs 49-year-old, P < 0.001) and mostly males (69% vs 49.7%, P < 0.001). After adjusting for these factors, CE patients had lower total charges compared to non-CE (US$ 21,589 vs. 30,291 P < 0.001) (Figure 1a). CE patients were also hospitalized for fewer number of days when compared to non-CE patients (3.84 vs 5.19 days). There was a significant downward trend in the prevalence of chronic pancreatitis admissions ( P < 0.001) amongst non-CE patients while there was an upward trend in the prevalence of chronic pancreatitis admissions amongst CE patients (Figure 2a, b). Interestingly, after matching for age, gender and comorbidities – CE patients had lower inpatient mortality ( P = 0.059). CONCLUSION: In patients admitted with a primary diagnosis of CP, CE patients had fewer length of stay, hospitalization cost and inpatient mortality. The interplay of these factors remains unknown and studies looking at cannabis strength/dose, route and consumption frequency are needed.
38 Does Cannabis Consumption Impact Chronic Pancreatitis Related Complications?
Mbachi, Chimezie , Wang, Yuchen , Barkin, Jodie A. , Demetria, Melchor , Barkin, Jamie S. , Kröner, Paul T. , Simons-Linares, C. Roberto

Mayo Clinic

American Journal of Gastroenterology | October 8, 2019 | Volume: 114 | Issue: 1 | Pages: S21-S22

10.14309/01.ajg.0000589684.01151.20 Get It

INTRODUCTION: Chronic pancreatitis (CP) does not currently have a cure and it leads to multiple complications (pain, exocrine pancreatic insufficiency, steatorrhea, bone disease), its management is still a challenge. There is evidence that stimulating the endocannabinoid system may reduce inflammation and fibrosis in pancreatic stellate cells. Cannabis is the most frequently used recreational drug in the US and in recent years its legalization has increased. There are currently multiple States in the US that have approved medical cannabis for CP. We investigate the prevalence and outcomes of CP-related complications amongst cannabis-exposed (CE) and non-cannabis-exposed (non-CE) CP patients. METHODS: The National Inpatient Sample (NIS) database from 2005 to 2014 was queried for all patients with a primary or secondary discharge diagnosis of chronic pancreatitis as per the International Classification of Diseases 9 th revision (ICD-9) code 577.1 and a complication related to chronic pancreatitis. Active exposure to cannabis was ascertained based on ICD-9 code 304.3X and 305.2X. We compared CE vs. non-CE patients. Outcomes included pancreatic cancer diagnosis, biliary stricture, pancreatic duct stricture, cholangitis, endoscopic retrograde cholangiopancreatography (ERCP) use for either diagnostic or therapeutic purpose. Propensity match analysis for age, gender, race, median income quartile, hospital characteristics and Elixhauser comorbidity index and multivariable logistic regression models were performed using SAS software (STATA 14). RESULTS: 109,326 patients with CP were analyzed (Figure 1). Prevalence of CE was 2.2% (2360 patients). The mean age of CP patients was 49. When comparing CE vs. non-CE, the CP-related complications amongst matched cohorts were as follows chronic abdominal pain 5.2% vs 0.3% ( P < 0.001), steatorrhea/diarrhea 1.2% vs 13.5% ( P < 0.001), biliary stricture 0.3% vs. 7.1% ( P < 0.001), pancreatic cancer 0.4% vs. 11.8% ( P < 0.001), cholangitis (0.1% vs 2.6%; P < 0.001), pancreatic cancer (0.4 vs 11.8; P < 0.001). Cannabis users also required less diagnostic ERCP (1.4% vs 5.5%; P < 0.001) and therapeutic ERCP (3.5% vs 9.3%; P < 0.001) (Figure 2). CONCLUSION: In CP patients admitted to the hospital, CE patients had lower rates of CP-related complications and importantly pancreatic cancer. These effects could possibly be through the effect of cannabis in the endocannabinoid system as previously shown in mice studies in Germany. More studies are needed to corroborate our findings.
Deep Learning for Automating the Organization of Institutional Dermatology Image Stores
Wang, Michael Z. , Comfere, Nneka I. , Murphree, Dennis H.

Mayo Clinic

2019 41st Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) | October 8, 2019 | Volume: No volume available | Issue: No issue available | Pages: 4479-4482

10.1109/embc.2019.8857086 | PMID 31946860 Get It

Sex-specific impact of patterns of imageable tumor growth on survival of primary glioblastoma patients
Whitmire, Paula , Rickertsen, Cassandra , Lorence, Julia, León, Gustavo De , Bayless, Spencer, Clark-Swanson, Kamala , Corpuz, Christina, Angeles, Christine Paula Lewis-de los, Bendok, Bernard R. , Vora, Sujay A., Mrugała, Maciej M. , Hu, Leland , Porter, Alyx B. , Kumthekar, Priya , Johnston, Sandra K. , Egan, Kathleen M. , Canoll, Peter , Swanson, Kristin R. , Swanson, Kristin R , Hawkins‐Daarud, Andrea , Carrasco, Eduardo, Leon, Gustavo De, Curtin, Lee , Peeri, Noah Charles , Gonzalez‐Cuyar, Luis F. , Wang, Lei G. , Gatenby, Robert A. , Rubin, Joshua B

Mayo Clinic

No container title available | October 2, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.2.10177/v2 Get It

Abstract Background : Sex is recognized as a significant determinant of outcome among glioblastoma patients, but the relative prognostic importance of glioblastoma features has not been thoroughly explored for sex differences. Methods : Combining multi-modal MR images, biomathematical models, and patient clinical information, this investigation assesses which pretreatment variables have a sex-specific impact on the survival of glioblastoma patients (299 males and 195 females). Results : Among males, tumor (T1Gd) radius was a predictor of overall survival (HR=1.027, p=0.044). Among females, higher tumor cell net invasion rate was a significant detriment to overall survival (HR=1.011, p<0.001). Female extreme survivors had significantly smaller tumors (T1Gd) (p=0.010 t-test), but tumor size was not correlated with female overall survival (p=0.955 CPH). Both male and female extreme survivors had significantly lower tumor cell net proliferation rates than other patients (M p=0.004, F p=0.001, t-test). Additionally, extent of resection, tumor laterality, and IDH1 mutation status were also found to have sex-specific effects on overall survival. Conclusion : Despite similar distributions of the MR imaging parameters between males and females, there was a sex-specific difference in how these parameters related to outcomes.
Chromatin Assembly Factor 1 (CAF-1) facilitates the establishment of facultative heterochromatin during pluripotency exit
Cheng, Liang , Zhang, Xu , Wang, Yan , Gan, Haiyun , Xu, Xiaowei , Lv, Xiangdong , Que, Jianwen , Ördög, Tamás , Zhang, Zhiguo , Zhang, Zhiguo , Hua, Xu , Que, Jianwen

Mayo Clinic

Nucleic Acids Research | October 2, 2019 | Volume: 47 | Issue: 21 | Pages: 11114-11131

10.1093/nar/gkz858 | PMID 31586391 Get It

Abstract Establishment and subsequent maintenance of distinct chromatin domains during embryonic stem cell (ESC) differentiation are crucial for lineage specification and cell fate determination. Here we show that the histone chaperone Chromatin Assembly Factor 1 (CAF-1), which is recruited to DNA replication forks through its interaction with proliferating cell nuclear antigen (PCNA) for nucleosome assembly, participates in the establishment of H3K27me3-mediated silencing during differentiation. Deletion of CAF-1 p150 subunit impairs the silencing of many genes including Oct4, Sox2 and Nanog as well as the establishment of H3K27me3 at these gene promoters during ESC differentiation. Mutations of PCNA residues involved in recruiting CAF-1 to the chromatin also result in defects in differentiation in vitro and impair early embryonic development as p150 deletion. Together, these results reveal that the CAF-1-PCNA nucleosome assembly pathway plays an important role in the establishment of H3K27me3-mediated silencing during cell fate determination.
Inherited variants at 3q13.33 and 3p24.1 are associated with risk of diffuse large B-cell lymphoma and implicate immune pathways
Kleinstern, Geffen , Yan, Huihuang , Berndt, Sonja I. , Ghesquières, Hervé , McKay, James , Wang, Sophia , Nieters, Alexandra, Ye, Yuanqing , Monnereau, Alain , Brooks‐Wilson, Angela , Lan, Qing , Melbye, Mads , Jackson, Rebecca D. , Purdue, Mark P. , Vajdic, Claire M. , Vermeulen, Roel , Cocco, Pier Luigi, Birmann, Brenda M. , Zeleniuch‐Jacquotte, Anne , Crouch, Simon , Sarangi, Vivekananda , Asmann, Yan W. , Offit, Kenneth , Salles, Gilles , Wu, Xifeng , Smedby, Karin E. , Skibola, Christine F., Rothman, Nathaniel , Cocco, Pierluigi , Asmann, Yan, Cocco, Pierluigi , Brooks-Wilson, Angela R , Vajdic, Claire M , Salles, Gilles A , Wang, Sophia S , Birmann, Brenda M , Zeleniuch-Jacquotte, Anne , Hildebrandt, Michelle A.T. , Vijai, Joseph , Teras, Lauren R. , Giles, Graham G. , Kraft, Peter , Albanes, Demetrius , Zhang, Yawei , Slager, Susan L. , Chanock, Stephen Jacob , Cerhan, James R.

Mayo Clinic

Human Molecular Genetics | October 1, 2019 | Volume: 29 | Issue: 1 | Pages: 70-79

10.1093/hmg/ddz228 | PMID 31600786 Get It

Abstract We previously identified five single nucleotide polymorphisms (SNPs) at four susceptibility loci for diffuse large B-cell lymphoma (DLBCL) in individuals of European ancestry through a large genome-wide association study (GWAS). To further elucidate genetic susceptibility to DLBCL, we sought to validate two loci at 3q13.33 and 3p24.1 that were suggestive in the original GWAS with additional genotyping. In the meta-analysis (5662 cases and 9237 controls) of the four original GWAS discovery scans and three replication studies, the 3q13.33 locus (rs9831894; minor allele frequency [MAF] = 0.40) was associated with DLBCL risk [odds ratio (OR) = 0.83, P = 3.62 × 10−13]. rs9831894 is in linkage disequilibrium (LD) with additional variants that are part of a super-enhancer that physically interacts with promoters of CD86 and ILDR1. In the meta-analysis (5510 cases and 12 817 controls) of the four GWAS discovery scans and four replication studies, the 3p24.1 locus (rs6773363; MAF = 0.45) was also associated with DLBCL risk (OR = 1.20, P = 2.31 × 10−12). This SNP is 29 426-bp upstream of the nearest gene EOMES and in LD with additional SNPs that are part of a highly lineage-specific and tumor-acquired super-enhancer that shows long-range interaction with AZI2 promoter. These loci provide additional evidence for the role of immune function in the etiology of DLBCL, the most common lymphoma subtype.
Reaction to Clindamycin Causing Laryngitis and Esophagitis
Rutt, Amy L. , Wang, Charis , Wang, Charis E, Rutt, Amy L.

Mayo Clinic

Ear, Nose & Throat Journal | October 1, 2019 | Volume: 100 | Issue: 6 | Pages: 437-438

10.1177/0145561319875138 | PMID 31569974 Get It

Integration of Machine Learning and Pharmacogenomic Biomarkers for Predicting Response to Antidepressant Treatment: Can Computational Intelligence be used to Augment Clinical Assessments?
Athreya, Arjun P. , Wang, Liewei , Weinshilboum, Richard M. , Bobo, William V. , Iyer, Ravishankar K. , Weinshilboum, Richard M.

Mayo Clinic

Pharmacogenomics | September 27, 2019 | Volume: 20 | Issue: 14 | Pages: 983-988

10.2217/pgs-2019-0119 | PMID 31559920 Get It